Befrena™

What is Befrena?

Befrena is a sterile liquid injectable caninized monoclonal antibody (mAb) that has been shown to be effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis (CAD).

What is the mechanism of action of Befrena?

Befrena is a caninized monoclonal antibody (mAb) that specifically targets and neutralizes canine interleukin-31 (IL-31), a key cytokine involved in sending itch signals to the brain. This targeted action provides relief from allergic itch by blocking a primary signal pathway, without broadly suppressing the immune system. Watch MOA Video.

What is the typical duration of effect for Befrena?

Clinical studies demonstrated that Befrena provides significant itch relief in the majority of dogs for 6 to 8 weeks following a single subcutaneous injection. The timing of subsequent injections may be adjusted based on the individual patient's clinical response and needs.

How quickly can improvement be expected after administering Befrena?

Befrena offers a rapid onset of clinical effect achieved within 24 hours.

How do I administer Befrena, and what are the dosing guidelines?

Aseptically withdraw the full volume from the appropriate vial(s) according to the dosing chart. Repeat administration every 6-8 weeks or as needed in individual patients based on clinical assessment and owner’s feedback on the dog’s itch status